GLP-1 Newsroom is your go-to source for breaking news, expert updates, trends, products, and real-world insights on everything related to GLP-1 medications, journeys, and diets.
The race to develop effective oral GLP-1 medications for obesity is heating up, and AstraZeneca is officially making its move. If you're like me, that means you're also seeing hope that the out-of-pocket costs of these medications, which include Ozempic, Zepbound, and Wegovy, will go down in the future as more players enter the field. At the 2026 American Diabetes Association Scientific Sessions, AstraZeneca announced positive Phase 2b results for elecoglipron. The medication
